We exposed BRAF mutant melanoma cell lines A375, WM115, and WM983B to increasing concentrations of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib (Figure 1A). This evidence concerns the gene MAP2K7 and melanoma.